The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.

Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive non-muscle invasive bladder cancer.

Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.

Daniel C. McFarland, DO, and Ramy Sedhom, MD, discussed co-located psycho-oncology and palliative care, warm handoffs, and proactive distress screening.

Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.

Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.

Ursula A. Matulonis, MD, surveyed the exploitable genetic changes driving the next wave of ovarian cancer trials, from CDK2 and WEE1 inhibitors to PARG inhibitors.

Ponatinib plus blinatumomab may help “a meaningful subset of patients” forego transplant for Ph-positive acute lymphoblastic leukemia.